3 September 2025 in The Lancet Regional Health - Americas
Radiation late toxicities (RLTs) are complications of curative-intent radiotherapy (RT) for head and neck cancer (HNC) and are increasingly relevant due to younger age at diagnosis and improved survival outcomes. We conducted a cohort study of HNC patients who received ≥50 Gy as part of curative treatment between January 2003 and December 2020 at a Canadian quaternary cancer center. Risk factors for severe RLTs (≥RTOG Grade 3) were evaluated using time-to-event analyses. Actuarial rates of RLT and overall survival (OS) were estimated using competing risk and Kaplan–Meier methods, respectively. Cox proportional hazard models identified factors associated with RLT and OS. Among 7622 patients, 12.6% (n = 958) developed RLTs without disease progression, with a 5-year actuarial incidence of 16% (95% CI: 15–16). A survivors subgroup (n = 4650) with ≥2 years of follow-up and no recurrence was also identified. Modifiable risk factors for RLTs included RT technique, dose, neck irradiation, neck dissection, smoking status, and chemotherapy (p ≤ 0.012). Non-modifiable factors included younger age, female sex, and oral cavity primaries (p ≤ 0.012). In multivariable analysis, RLTs were associated with increased mortality (HR = 2.1, 95% CI: 1.8–2.5, p < 0.001), but RLT's impact on OS was lessened among patients referred to the Adult Radiation Late Effects Clinic (ARLEC) (HR = 1.7, 95% CI: 1.3–2.4). RLTs are common and associated with worse survival among HNC survivors. Identification of modifiable risk factors provides opportunities for prevention. Multidisciplinary management of RLTs in specialized clinics may help improve the outcomes in this growing survivorship population. No external funding was utilized for this study.
23 August 2024 in Oral Oncology
21 April 2025 in Oral Oncology
14 May 2026 in Oral Oncology
17 September 2025 in Technical Innovations & Patient Support in Radiation Oncology
Reirradiation is an increasingly common challenge with limited prospective evidence to guide practice, which varies internationally. This paper presents the patterns of practice in thoracic reirradiation within a high-volume academic center. Thoracic reirradiation cases, discussed at the thoracic radiotherapy quality assurance (QA) meeting, were prospectively collected over 12 months between April 2024 and March 2025. Data collected included patient demographics, primary tumor site, details of previous and current planned radiotherapy, the extent and type of overlap and any treatment plan modifications. The data was analyzed using descriptive statistics. 85 (18.2 % of 466 cases) reirradiation cases were identified at 26 QA meetings. Most reirradiation plans (68.2 %) were of radical intent, with dose overlap (89.4 %, n = 76). Challenges included unreliable registration of prior radiotherapy datasets (16.5 %) and deciding appropriate plan modifications to improve safety: 24.7 % optimized dose distribution to an OAR, 23.5 % involved dose reductions from standard prescriptions and 15.3 % compromised target volume coverage. The most frequently identified dose-limiting OARs were the proximal bronchial tree, esophagus, and spinal cord. Concerns about a lack of normal tissue recovery arose in 7.1 % of cases. In 10.6 % of cases there was explicit discussion of a dose discount for OARs for presumed partial tissue recovery. Peer-review prompted revision of the treatment plan in 11.8 % of cases. These findings underscore the complexity of thoracic reirradiation and highlight the need for further guidance in the area and the role of QA rounds in optimizing safety and treatment decisions while best practice remains uncertain.